Skip to main navigation Skip to search Skip to main content

N-Adamantyl Phthalimidine: A New Thalidomide-like Drug That Lacks Cereblon Binding and Mitigates Neuronal and Synaptic Loss, Neuroinflammation, and Behavioral Deficits in Traumatic Brain Injury and LPS Challenge

  • Shih Chang Hsueh
  • , Weiming Luo
  • , David Tweedie
  • , Dong Seok Kim
  • , Yu Kyung Kim
  • , Inho Hwang
  • , Jung-Eun Gil
  • , Baek-Soo Han
  • , Yung-Hsiao Chiang
  • , Warren Selman
  • , Barry J Hoffer
  • , Nigel H Greig

Research output: Contribution to journal › Article › peer-review

Abstract

Neuroinflammation contributes to delayed secondary cell death following traumatic brain injury (TBI), has the potential to chronically exacerbate the initial insult, and represents a therapeutic target that has largely failed to translate into human efficacy. Thalidomide-like drugs have effectively mitigated neuroinflammation across cellular and animal models of TBI and neurodegeneration but are complicated by adverse actions in humans. We hence developed N-adamantyl phthalimidine (NAP) as a new thalidomide-like drug to mitigate inflammation without binding to cereblon, a key target associated with the antiproliferative, antiangiogenic, and teratogenic actions seen in this drug class. We utilized a phenotypic drug discovery approach that employed multiple cellular and animal models and ultimately examined immunohistochemical, biochemical, and behavioral measures following controlled cortical impact (CCI) TBI in mice. NAP mitigated LPS-induced inflammation across cellular and rodent models and reduced oligomeric α-synuclein and amyloid-β mediated inflammation. Following CCI TBI, NAP mitigated neuronal and synaptic loss, neuroinflammation, and behavioral deficits, and is unencumbered by cereblon binding, a key protein underpinning the teratogenic and adverse actions of thalidomide-like drugs in humans. In summary, NAP represents a new class of thalidomide-like drugs with anti-inflammatory actions for promising efficacy in the treatment of TBI and potentially longer-term neurodegenerative disorders.

Original languageEnglish
Pages (from-to)980-1000
Number of pages21
JournalACS pharmacology & translational science
Volume4
Issue number2
DOIs
StatePublished - Apr 9 2021
Externally publishedYes

Cite this